Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

FLEXISEQ® Sport launches in the UK
  • USA - English


News provided by

Pro Bono Bio

Jan 22, 2015, 09:15 ET

Share this article

Share toX

Share this article

Share toX

New FLEXISEQ Sport
New FLEXISEQ Sport

London (PRWEB UK) 22 January 2015 -- FLEXISEQ Sport launches today in the UK, for all active people (including athletes and members of the armed forces), who want to protect and care for their joints.

Drug-free FLEXISEQ Sport is screened to be free of any trace substances banned by the World Anti-Doping Agency (WADA) and comes in a hotly anticipated 100g pack-size to treat and protect multiple joints.

FLEXISEQ Sport offers everyone the safe option in pain relief and joint maintenance. Everyone, young or old, professional or amateur, needs to stay mobile for a fit, productive and happy life.

Post this

Regular exercise can place strain on joints and FLEXISEQ Sport allows users to stay active without the distraction of joint pain and stiffness, overuse of painkillers or worries about doping. The product has been tested in the hardest impact sports to ensure it can meet any challenge.

FLEXISEQ Sport is suitable for all active people and has been tested on and developed with professional athletes, across many sporting disciplines to manage joint pain and restore function, without the use of drugs. While the product is clinically proven to relieve the symptoms of all stages of osteoarthritis, including pain and stiffness, its use in sport has generated some remarkable examples of injury rehabilitation.

Shaun Barker, Derby County FC Club Captain said, “Almost three years ago I suffered an injury that was considered career ending. I ruptured all ligaments in my knee and suffered cartilage damage. Since then I have been on an intense rehabilitation programme and I am delighted to say that I am now back to training with the U21 squad. FLEXISEQ Sport has helped me deal with the pain and stiffness I regularly experienced in my knee, especially after a more intense rehab session. I use FLEXISEQ Sport at least twice a day to keep my recovery on track.”

John Mayo, CEO of Pro Bono Bio said, “Use of pharmaceuticals is an unsatisfactory option to manage joint pain as they only mask the pain and can cause side effects. Just last week oral diclofenac was forced off the shelves to prescription-only status, due to serious heart risks. The overuse of NSAIDs in sport is well known to be a problem. FLEXISEQ Sport offers everyone the safe option in pain relief and joint maintenance. Everyone, young or old, professional or amateur, needs to stay mobile for a fit, productive and happy life.”

Saracens, England and British & Irish Lions rugby player, Brad Barritt and Northampton Saints, England and British & Irish Lion, Alex Corbisiero, are two elite athletes who use FLEXISEQ Sport as part of their preparation and recovery programmes, in addition to a number of professional rugby clubs including Leicester Tigers and Saracens. Overseas, FLEXISEQ Sport is being used by German international ski jumper Ulrike Gräßler, while ex- South African international cricketer Neil McKenzie uses the product to relieve his knee pain.

England centre Brad Barritt, said, “This product has been an absolute revelation since I started using it – it’s a key part of my conditioning and my game preparations and it’s good to know that it meets the strict anti-doping standards.”

Ulrike Gräßler said, “I experience extraordinary forces on my knees when I jump. Over 16 years of competition, these forces have taken their toll on my knees. I can’t take risks with drugs and medical products, so FLEXISEQ Sport helps me avoid pain and stiffness. I feel like my knees are protected by cotton wool”.

Nick Baverstock, Director of Sports at Pro Bono Bio said, “FLEXISEQ Sport has been launched to satisfy the demand we’ve had from active people for a product that protects their joints from pain and stiffness. Professional and other serious athletes know the product not only alleviates joint pain and restores physical function but also can be used with confidence that it meets the strictest anti-doping rules of sport and other spheres of life. FLEXISEQ Sport can help look after the joints of anyone wanting to stay active.”

FLEXISEQ Sport is available at all Lloyds Pharmacies from 1st February and from good retailers from mid-March 2015.

For further information please contact:

John Mayo    
Pro Bono Bio
+44 20 7291 5456                                                    
karen(dot)frost(at)pbbio(dot)com

Michael Earl
Pro Bono Bio
+44 20 7291 5446
lucy(dot)parker(at)pbbio(dot)com

About FLEXISEQ® Sport:

FLEXISEQ Sport is the sister brand of the revolutionary osteoarthritis product, FLEXISEQ. Continuing its pioneering heritage in treating joint pain and stiffness, the product has been developed in collaboration with professional sportspeople in order to meet the demands of athletes and other active people. Every batch of FLEXISEQ Sport has been screened and cleared for substances that are banned by the World Anti-Doping Agency (WADA).

About FLEXISEQ®:

FLEXISEQ is a topically applied drug-free gel which is clinically proven to safely relieve the pain and improve the joint stiffness associated with osteoarthritis (OA). There is extensive clinical data available from several randomised, double-blind clinical trials and FLEXISEQ is approved as a medical device for the treatment of all joints affected by OA.

FLEXISEQ is unique - it lubricates your joints to address joint damage. Pain is relieved and joint function improved because it lubricates away the friction and associated wear and tear on a user’s joints.

About Pro Bono Bio:

Pro Bono Bio plc is the world’s leading nanotechnology company offering health and lifestyle products, headquartered in London with operations in Europe, Africa and Asia and due to launch in CIS and North America.

About the Withdrawal of Diclofenac:

14th January, 2015: MHRA announces that diclofenac was associated with an “increased risk of heart problems” and reclassified the drug to “prescription only”. http://www.gov.uk/drug-device-alerts/drug-alert-oral-diclofenac-presentations-with-legal-status-p-reclassified-to-pom

About Active Lifestyles:

13th January, 2015: a large study report was published on the importance of an active lifestyle on health and longevity. Am J Clin Nutr doi:10.3945/ajcn.114.100065.

Michael Earl, Pro Bono Bio, +44 2072915446, [email protected]

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.